Rafael E. Curiel

1.1k total citations
22 papers, 847 citations indexed

About

Rafael E. Curiel is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Rafael E. Curiel has authored 22 papers receiving a total of 847 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 11 papers in Immunology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Rafael E. Curiel's work include Immune Cell Function and Interaction (7 papers), Cytokine Signaling Pathways and Interactions (6 papers) and T-cell and B-cell Immunology (4 papers). Rafael E. Curiel is often cited by papers focused on Immune Cell Function and Interaction (7 papers), Cytokine Signaling Pathways and Interactions (6 papers) and T-cell and B-cell Immunology (4 papers). Rafael E. Curiel collaborates with scholars based in United States, Italy and Canada. Rafael E. Curiel's co-authors include Robert J. Motzer, Premal H. Patel, Coleman K. Obasaju, Howard A. Young, Bruce J. Roth, Christopher J. Sweeney, David J. Vaughn, Steven J. Nicol, Donald S. Kaufman and Yanping Wang and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Rafael E. Curiel

22 papers receiving 836 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rafael E. Curiel United States 15 337 266 248 225 206 22 847
Wing Y. Chan China 15 345 1.0× 152 0.6× 150 0.6× 167 0.7× 246 1.2× 25 802
H. J. Hassan Italy 20 146 0.4× 137 0.5× 328 1.3× 250 1.1× 90 0.4× 54 1.4k
Dominique Bories France 18 194 0.6× 123 0.5× 506 2.0× 404 1.8× 82 0.4× 33 1.5k
Ronald G. Crystal United States 9 244 0.7× 498 1.9× 444 1.8× 88 0.4× 209 1.0× 9 1.2k
Ashraf Imam Israel 16 127 0.4× 147 0.6× 272 1.1× 125 0.6× 126 0.6× 58 619
Ayako Fujiwara Japan 15 375 1.1× 444 1.7× 235 0.9× 65 0.3× 170 0.8× 37 895
Kotaro Miyake Japan 14 328 1.0× 120 0.5× 342 1.4× 205 0.9× 57 0.3× 59 864
Vittore Cereda Italy 18 859 2.5× 305 1.1× 352 1.4× 733 3.3× 104 0.5× 30 1.3k
C S Lee Australia 9 148 0.4× 112 0.4× 164 0.7× 199 0.9× 144 0.7× 9 631
Silke Schüle Germany 15 135 0.4× 118 0.4× 198 0.8× 103 0.5× 219 1.1× 43 676

Countries citing papers authored by Rafael E. Curiel

Since Specialization
Citations

This map shows the geographic impact of Rafael E. Curiel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rafael E. Curiel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rafael E. Curiel more than expected).

Fields of papers citing papers by Rafael E. Curiel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rafael E. Curiel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rafael E. Curiel. The network helps show where Rafael E. Curiel may publish in the future.

Co-authorship network of co-authors of Rafael E. Curiel

This figure shows the co-authorship network connecting the top 25 collaborators of Rafael E. Curiel. A scholar is included among the top collaborators of Rafael E. Curiel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rafael E. Curiel. Rafael E. Curiel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Spira, Alexander I., Xiaolei Zhou, Lei Chen, et al.. (2021). Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 22(3). 158–168. 8 indexed citations
2.
Spira, Alexander I., Lei Chen, Xiaolei Zhou, et al.. (2020). Symptoms, Health-Related Quality of Life, and Tolerability of Loncastuximab Tesirine in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma. Blood. 136(Supplement 1). 3–4. 1 indexed citations
3.
Rose, April A. N., Marco Biondini, Rafael E. Curiel, & Peter M. Siegel. (2017). Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer. Pharmacology & Therapeutics. 179. 127–141. 67 indexed citations
4.
Alemao, E., Srinivasan Rajagopalan, Shi‐Yi Yang, et al.. (2011). Inverse probability weighting to control for censoring in a post hoc analysis of quality-adjusted survival data from a clinical trial of temsirolimus for renal cell carcinoma. Journal of Medical Economics. 14(2). 245–252. 1 indexed citations
5.
Dancey, Janet, Rafael E. Curiel, & J. Purvis. (2009). Evaluating Temsirolimus Activity in Multiple Tumors: A Review of Clinical Trials. Seminars in Oncology. 36. S46–S58. 42 indexed citations
6.
Patel, Premal H., et al.. (2009). Phase I Study Combining Treatment with Temsirolimus and Sunitinib Malate in Patients with Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer. 7(1). 24–27. 131 indexed citations
7.
8.
Masters, Gregory A., Athanassios Argiris, Elizabeth A. Hahn, et al.. (2006). A Randomized Phase II Trial Using Two Different Treatment Schedules of Gemcitabine and Carboplatin in Patients with Advanced Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 1(1). 19–24. 1 indexed citations
9.
Masters, Gregory A., Athanassios Argiris, Elizabeth A. Hahn, et al.. (2006). A Randomized Phase II Trial Using Two Different Treatment Schedules of Gemcitabine and Carboplatin in Patients with Advanced Non???Small-Cell Lung Cancer. Journal of Thoracic Oncology. 1(1). 19–24. 16 indexed citations
10.
Sweeney, Christopher J., Bruce J. Roth, Fairooz F. Kabbinavar, et al.. (2006). Phase II Study of Pemetrexed for Second-Line Treatment of Transitional Cell Cancer of the Urothelium. Journal of Clinical Oncology. 24(21). 3451–3457. 191 indexed citations
11.
Obasaju, Coleman K., Zhishen Ye, L. P. Bloss, Matthew Monberg, & Rafael E. Curiel. (2005). Gemcitabine/Carboplatin in Patients with Metastatic Non–Small-Cell Lung Cancer: Phase II Study of 28-Day and 21-Day Schedules. Clinical Lung Cancer. 7(3). 202–207. 8 indexed citations
12.
Curiel, Rafael E., et al.. (2005). Interleukin-12 (IL-12) ameliorates the effects of porcine respiratory and reproductive syndrome virus (PRRSV) infection. Veterinary Immunology and Immunopathology. 107(1-2). 105–118. 33 indexed citations
13.
Zinner, Ralph, Frank V. Fossella, Gregory W. Gladish, et al.. (2005). Phase II study of pemetrexed in combination with carboplatin in the first‐line treatment of advanced nonsmall cell lung cancer. Cancer. 104(11). 2449–2456. 74 indexed citations
14.
Curiel, Rafael E., et al.. (2001). Bryostatin-1 and IL-2 Synergize to Induce IFN-γ Expression in Human Peripheral Blood T Cells: Implications for Cancer Immunotherapy. The Journal of Immunology. 167(9). 4828–4837. 25 indexed citations
15.
Bosco, Maria Carla, Rafael E. Curiel, Arnold H. Zea, et al.. (2000). IL-2 Signaling in Human Monocytes Involves the Phosphorylation and Activation of p59 hck. The Journal of Immunology. 164(9). 4575–4585. 26 indexed citations
16.
Yu, Cheng‐Rong, John R. Ortaldo, Rafael E. Curiel, et al.. (1999). Role of a STAT Binding Site in the Regulation of the Human Perforin Promoter. The Journal of Immunology. 162(5). 2785–2790. 62 indexed citations
17.
18.
Curiel, Rafael E., et al.. (1998). Cytokines Produced Early in Picornavirus Infection Reflect Resistance or Susceptibility to Disease. Journal of Interferon & Cytokine Research. 18(8). 587–596. 14 indexed citations
19.
Curiel, Rafael E., Riitta Lahesmaa, Jeff Subleski, et al.. (1997). Identification of a Stat‐6‐responsive element in the promoter of the human interleukin‐4 gene. European Journal of Immunology. 27(8). 1982–1987. 46 indexed citations
20.
Curiel, Rafael E., et al.. (1993). Does the Gender Difference in Interferon Production Seen in Picornavirus-Infected Spleen Cell Cultures from ICR Swiss Mice Have Any In Vivo Significance?. Journal of Interferon Research. 13(6). 387–395. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wing Y. Chan Breakdown of academic impact, for papers by H. J. Hassan Breakdown of academic impact, for papers by Dominique Bories Breakdown of academic impact, for papers by Ronald G. Crystal Breakdown of academic impact, for papers by Ashraf Imam Breakdown of academic impact, for papers by Ayako Fujiwara Breakdown of academic impact, for papers by Kotaro Miyake Breakdown of academic impact, for papers by Vittore Cereda Breakdown of academic impact, for papers by C S Lee Breakdown of academic impact, for papers by Silke Schüle
Rankless by CCL
2026